Xtandi approved in Japan for CRPC
This article was originally published in Scrip
Astellas has received marketing approval in Japan for Xtandi (enzalutamide) for use in previously treated patients with castration-resistant prostate cancer (CRPC), marking the first such clearance in this market for the oral androgen receptor signalling inhibitor.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.